Listen to an indepth conversation between the ANCHOR Study's Protocol Chair and Professor of Medicine at UCSF, Dr. Joel Palefsky, and the Director
Hear a key conversation between ANCHOR Study investigator, Dr. Jessica Korman, and The BodyPro's, Miles Helfand, about how the ANCHOR Study is
The incidence of anal cancer is substantially higher among persons living with the human immunodeficiency virus (HIV) than in the general
Prompt detection and treatment of precancerous lesions cut the likelihood of developing anal cancer by more than half.
Subjects with HIV who had precancerous lesions and got proactive treatment had a 57% lower rate of progressing to cancer.
HPV (human papillomavirus) is associated with 630,000 cancer diagnoses around the world. Almost all cases of cervical and anal cancers are caused
Screening for precancerous anal cell changes and treating them early lowers the risk of progression to anal cancer in people living with HIV,
Prompt treatment of precancerous lesions reduced the likelihood of developing anal cancer by 57%.
A protocol in which high-grade squamous intraepithelial lesions (HSIL) of the anal canal were immediately treated was more effective for
Treating high-grade squamous intraepithelial lesions — primarily with office-based electrocautery — led to an almost 60% reduction in anal cancer